| View |
|
BR-1276
|
Human Albumin
|
Alburx
|
250 g/L (25 % w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring AG
|
Switzerland
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Automatic Renewal
|
05 January 2023
|
07 June 2028
|
| View |
|
BR-1277
|
Human Albumin
|
Alburx
|
200 g/L (20% w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring LLC
|
U.S.A.
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
BR-1277
|
03 January 2023
|
07 June 2028
|
| View |
|
BR-1278
|
Human Albumin
|
Alburx
|
250 g/L (25% w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring LLC
|
U.S.A.
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
BR-1278
|
31 December 2022
|
07 June 2028
|
| View |
|
BR-1279
|
Etanercept
|
Etveza 25
|
25mg
|
Lyophilized Powder for Subcutaneous Injection
|
Prescription Drug (Rx)
|
USP Type I Clear glass Vial with
colored flip-off seal x 2mL (Box of 1's)
|
Immunosuppressant/ Tumor
Necrosis Factor Alpha Inhibitor
|
Shangpai CP Guojian Pharmaceutical Co., Ltd
|
China
|
|
Metro Drug, Inc.
|
Metro Drug, Inc.
|
Initial (Compliance)
|
19 November 2019
|
11 July 2024
|
| View |
|
BR-1280
|
Atezolizumab
|
Tecentriq
|
60 mg/mL (1.2 g/20 mL)
|
Concentrate for Solution for
Infusion
|
Prescription Drug (RX)
|
Type I glass vial with rubber stopper and aluminum
seal with flip-off cap x 20 mL (Box of 1's)
|
-
|
Roche Diagnostics GmbH
|
Germany
|
N/A
|
Roche (Philippines) Inc.
|
N/A
|
Monitored Release (Variation)
|
22 February 2023
|
22 February 2028
|
| View |
|
BR-1282
|
Eptacog alfa activated
|
NovoSeven RT
|
1 mg/vial (50KIU/vial)
|
Powder And Solvent For Solution For Injection
|
Prescription Drug (RX)
|
Vial: Type I glass vial closed with chlorobutyl rubber stopper, covered with an aluminium cap. The closed vial is equipped with a polypropylene tamper-evident snap-off cap. Pre-filled syringe: Type I glass barrel with a polypropylene backstop and bromobutyl rubber plunger. The syringe cap consists of bromobutyl rubber and polypropylene tamper evident seal. Plunger rod: made of polypropylene.
|
Blood Coagulation Factor
|
Novo Nordisk A/S
|
Denmark
|
|
Novo Nordisk Pharmaceuticals (Philippines) Inc.
|
|
Renewal
|
01 August 2023
|
25 July 2028
|
| View |
|
BR-1284
|
Isophane Insulin (Recombinant DNA)
|
Humulin N
|
100 Units/mL
|
Suspension for Injection (SC)
|
Prescription Drug (RX)
|
Type I siliconized glass cartridge sealed with rubber closures consisting of a chlorobutyl plunger and an aluminum disc seal x 3 mL (Box of 5's)
|
-
|
Lilly France S.A.S.
|
France
|
N/A
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Renewal
|
11 October 2022
|
31 October 2027
|
| View |
BR-1287_PI_01.pdf
|
BR-1287
|
Ustekinumab
|
Stelara
|
45mg/ 0.5mL
|
Solution for Injection
|
Prescription Drug (Rx)
|
Type I pre-filled glass syringe (0.5mL net content) with needle and plunger stopper (Box of 1's)
|
-
|
Cilag AG
|
Switzerland
|
|
Johnson & Johnson (Phils.) Inc.
|
Zuellig Pharma Corporation
|
-
|
10 May 2019
|
10 May 2024
|
| View |
|
BR-1289
|
Rotavirus Vaccine (Live, Attenuated)
|
Rotasiil
|
Formulation: After reconstitution, each dose (2.5 mL) contains:
Live Attenuated Bovine-Human Rotavirus Reassortant [G1, G2, G3, G4 and G9]* >10^5.6 FFU/Serotype *Grown on vero cells
|
Freeze-dried Powder for Oral Suspension
|
Prescription Drug (RX)
|
Type I clear tubular glass vial + Type I glass vial x 2.5 mL (Citrate Bicarbonate buffer solution as diluent) (Box of 1's)
|
-
|
Serum Institute of India Private Limited
|
India
|
N/A
|
Faberco Life Sciences Inc.
|
N/A
|
-
|
18 March 2022
|
08 February 2027
|
| View |
|
BR-1290
|
Inactivated Poliomyelitis Vaccine (Types 1, 2 And 3)
|
Poliovac
|
0.5 mL
|
Suspension For Injection (IM/SC)
|
Prescription Drug (RX)
|
Type I Clear Vial x 0.5 mL (Box of 1's, 10's and 50's)
|
-
|
Serum Institute of India Private Limited
|
India
|
N/A
|
Faberco Life Sciences Inc.
|
Faberco Life Sciences Inc.
|
Initial (Variation)
|
09 February 2023
|
09 February 2028
|
| View |
BR-1291_PI_01.pdf
|
BR-1291
|
Liraglutide
|
SAXENDA
|
6mg/ mL
|
Solution for Injection
|
Prescription Drug (Rx)
|
Cartridge (type 1 glass) with a plunger (bromobutyl) and a stopper (bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polyacetal, polycarbonate and acrylonitrile butadiene styrene.
|
Anti-Obesity
|
NOVO NORDISK A/S
|
Denmark
|
|
NOVO NORDISK PHARMACEUTICALS (PHILS.) INC.
|
NOVO NORDISK PHARMACEUTICALS (PHILS.) INC.
|
Monitored Release
|
25 April 2019
|
25 April 2025
|
| View |
|
BR-1292
|
Rabies Vaccine Inactivated (Freeze Dried)
|
Rabivax-S
|
each dose contains nlt 2.5 IU
|
Solution For Intradermal Injection
|
Prescription Drug (RX)
|
4mL USP Type 1 glass vial
|
-
|
Serum Institute of India
|
India
|
|
Glovax Biotech Corp.
|
Glovax Biotech Corp.
|
-
|
06 May 2019
|
06 May 2024
|
| View |
|
BR-1293
|
Rituximab
|
Rituxikal (50)
|
500 mg/ 50 mL
|
Concentrate for Solution for Infusion
|
Prescription Drug (RX)
|
One 50 mL Type I borosilicate glass vial with chlorobutyl rubber stopper and alimunum flip-off foil seal a plastic tray (Box of 1's)
|
-
|
Sinergium Biotech S.A.
|
Argentina
|
|
Globo Asiatico Ent. Inc.
|
Globo Asiatico Ent. Inc.
|
-
|
24 May 2019
|
24 May 2024
|
| View |
|
BR-1294
|
Rituximab
|
Rituxikal
|
100 mg/ 10 mL
|
Concentrate for Solution for Infusion
|
Prescription Drug (RX)
|
Two 10 mL Type I borosilicate glass vial with chlorobutyl rubber stopper and alimunum flip-off foil seal a plastic tray (Box of 2's)
|
-
|
Sinergium Biotech S.A.
|
Argentina
|
|
Globo Asiatico Ent. Inc.
|
Globo Asiatico Ent. Inc.
|
-
|
24 May 2019
|
24 May 2024
|
| View |
|
BR-1296
|
Dulaglutide
|
Trulicity
|
0.75 mg/0.5 mL
|
Solution For Injection
|
Prescription Drug (RX)
|
0.5 mL Type I glass syringe barrel with 29 G x 1/2" needle in a pen delivery device (Box of 4's)
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
|
Zuellig Pharma Corp.
|
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
| View |
BR-1297_PI_01.pdf
|
BR-1297
|
Dulaglutide
|
Trulicity
|
1.5 mg/0.5 mL
|
Solution For Injection
|
Prescription Drug (Rx)
|
0.5 mL Type I glass syringe barrel with 29 G x 1/2" needle in a pen delivery device (Box of 4's)
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
|
Zuellig Pharma Corp.
|
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
| View |
BR-1298_PI_01.pdf
|
BR-1298
|
Ramucirumab
|
Cyramza
|
10 mg/mL
|
Concentrate For Solution For Infusion (IV)
|
Prescription Drug (RX)
|
Type I glass vial with a chlorobutyl elastomer stopper, enclosed with aluminum seal x 10mL and 50mL (Boz of 1's)
|
-
|
Eli Lilly & Company
|
United States of America
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Monitored Release
|
17 March 2022
|
02 July 2024
|
| View |
BR-1299_PI_01.pdf
|
BR-1299
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
1 mL Type I Clear Glass Syringe Barrel, with 27g X 1/2" Needle, in a Pen delivery device (Box of l's, 2's, and 3's + Physician Sample). Single dose.
|
-
|
Eli Lilly & Company
|
United States of America
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Monitored Release
|
17 March 2022
|
08 July 2024
|
| View |
BR-1300_PI_01.pdf
|
BR-1300
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
1mL Type I clear prefilled glass syringe with 27 G 1/2 needle (Box of 1's, 2's and 3's). Single dose.
|
-
|
Eli Lilly & Company
|
United States of America
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Monitored Release
|
17 March 2022
|
08 July 2024
|
| View |
BR-1301_PI_01.pdf
|
BR-1301
|
Daratumumab
|
Darzalex
|
20 mg/mL
|
Concentrate For Solution For Infusion (Iv)
|
Prescription Drug (Rx)
|
Type I Glass vial with an elastomeric Closure and an aluminum seal with a flip-off cap x 5mL and 20mL (Box of 1's)
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
|
Johnson & Johnson (Phils.), Inc.
|
|
-
|
01 August 2019
|
01 August 2024
|